Matthew Maxwell Donley insider trades

Open-market stock purchases and sales by Matthew Maxwell Donley, Chief Operating Officer at Aurinia Pharmaceuticals Inc, from SEC Form 4 filings since Mar 4, 2015.

Track record: 100% of 2 scored buys are up 5% or more since purchase, averaging +153%.

Recent trades

DateStockTradeValue
Mar 2, 2026AUPH Aurinia Pharmaceuticals IncSold (not open market)$579K
Feb 27, 2026AUPH Aurinia Pharmaceuticals IncBought (not open market)—
Feb 27, 2026AUPH Aurinia Pharmaceuticals IncBought (not open market)—
Feb 20, 2026AUPH Aurinia Pharmaceuticals IncSold (not open market)$474K
Jan 2, 2026AUPH Aurinia Pharmaceuticals IncBought (not open market)—
Jan 2, 2026AUPH Aurinia Pharmaceuticals IncSold (not open market)$682K

Companies traded

  • AUPH Aurinia Pharmaceuticals Inc: 2 buys, 4 sales, last Mar 2, 2026
  • SCMP Sucampo Pharmaceuticals, Inc: other filings, last Feb 13, 2018

Get free alerts when Matthew Maxwell Donley files a new trade →